BWXT Sharpens Focus on Nuclear: Divests Medical, Doubles Down on Commercial Capacity

Opening

BWXT reported a strong second quarter on August 3, with revenue up 18% and adjusted EPS up 5%, but the market has been unimpressed — the stock is down 31.7% over the last 90 days, hitting a drawdown of -34.2% from its April peak. The market's skepticism appears driven by margin compression and the heavy capital investment required to capture the nuclear super cycle, even as management sharpens its focus on the core nuclear franchise.

“We delivered another strong quarter, characterized by excellent execution across the company and continued momentum in commercial nuclear.” — Rex Geveden, President and CEO · 2026-08-03 But the real story is the portfolio reshape: BWXT is divesting its medical business to Nordic Capital for up to $800 million and simultaneously acquiring Precision Components Group (PCG) to expand its U.S. commercial manufacturing footprint. This is a deliberate pivot toward commercial capacity in nuclear power.

Strategic Pivot

The medical divestiture is the clearest signal of management's intent. Rex Geveden explained, “This transaction enables BWXT to sharpen its focus on our core nuclear national security and commercial nuclear power businesses” — Rex Geveden, President and CEO · 2026-08-03 — a move that will leave the company as a pure-play nuclear supplier. The sale includes just over 80% of BWXT Medical and Kinectrics' stable isotope enrichment businesses, retaining a minority stake and the Isogen joint venture. The deal is valued at up to $800 million, with $750 million in base consideration plus shared economics.

We announced the sale of our medical business to Nordic Capital at a valuation of up to $800 million. The transaction results in the sale of just over 80% of BWXT's Medical and Kinectrics' stable isotope enrichment businesses.

On the acquisition side, PCG (long lead item manufacturer) brings naval and commercial nuclear capabilities, adding ~$200 million of revenue and a qualified workforce. It gives BWXT a U.S.-based platform to capture outsourced work and support a growing pipeline of large component orders for SMRs and large reactors. This is part of a broader capacity expansion strategy that could include a new greenfield site near Mount Vernon, Indiana, or an East Coast location leveraging PCG's assets.

Commercial Nuclear Demand and Capacity

Management's confidence in commercial demand is palpable. “We believe there's a credible opportunity to secure at least one new build nuclear equipment order before the year-end.” — Rex Geveden, President and CEO · 2026-08-03 This could come from AP1000s, BWRX-300s at Darlington, or other SMR opportunities. The company is also monetizing its mPower technology through licensing deals with Applied Atomics (terrestrial) and Core Power (floating), preserving manufacturing rights and royalties. As Rex noted on the call, “fundamentally, what we're doing here is monetizing our IP” — Rex Geveden, President and CEO · 2026-08-03 — a low-capital way to participate in multiple reactor designs.

TRISO fuel remains a strategic option. After the Antares reactor achieved criticality using BWXT fuel, the company is evaluating a larger commercial investment in Wyoming. However, “we're not yet ready to make a full capital commitment on it” — Rex Geveden, President and CEO · 2026-08-03 — waiting for more solid order visibility, including the Janus program award expected this year.

The Core Power agreement and the long lead item opportunities underscore how BWXT is positioning itself as the merchant supplier of choice. Combined with the naval propulsion 'drop-in' battleship potential and the accelerated Ford-class cadence, the long-term growth narrative is compelling.

Financial Trade-offs

Management raised full-year adjusted EBITDA guidance by $10 million to $662–672 million and free cash flow guidance by $30 million to $345–360 million. However, the segment mix tells a more nuanced story. Government Operations revenue growth was revised down to high single digits (from low teens) due to better cost performance, but the segment's EBITDA margin target was raised to ~20.5% — a positive trade-off. In contrast, Commercial Operations revenue growth was raised to ~45% (including PCG), but its margin guide was cut to ~13% from 14% due to deliberate investments in U.S. capacity and executive talent.

The financial impact is visible in the fundamentals. Operating margin has declined from 14% a year ago to 12.5%, and gross margin is at 22.9%. These investments are essential to scale for the nuclear buildout, but they compress near-term profitability. As Mike Fitzgerald explained, “We are raising our adjusted EBITDA guidance by $10 million at the midpoint to a range of $662 million to $672 million” — Michael Fitzgerald, Senior Vice President and CFO · 2026-08-03 — solidly funded by operational performance, but the margin trajectory remains below prior cycle highs.

Importantly, the free cash flow outlook is improving, with FCF margin at 4.6% and strong backlog growth (40% yoy to $8.4 billion). The company's book-to-bill of 1.7x on a trailing twelve-month basis confirms robust demand. But the market is pricing in execution risk and margin dilution from the heavy capex (6-7% of sales) needed to build out new capacity.

The prior quarter's commentary foreshadowed this strategy. On the May 2026 call, Rex quipped, “we're betting on the race, not on the horse” — Rex Geveden, President and CEO · 2026-05-05 — a nod to serving multiple reactor vendors. Now, with the medical divestiture and PCG acquisition, the company is doubling down on that bet, accepting lower near-term margins for a shot at a multi-decade nuclear super cycle.

What Changed

The key change is the complete repositioning of BWXT as a nuclear pure-play. The sale of medical, the rapid integration of PCG, and the aggressive pursuit of U.S. commercial capacity signal a management team that is all-in on the nuclear renaissance. While the market has punished the stock during the transition, the long-term opportunity — including potential orders from AP1000 and SMR programs, TRISO fuel expansion, and the battleship program — could justify the near-term pain. The question is whether investors have the patience for the ~2-3 years of capacity buildout before the payoff.

As Rex said in his closing remarks, “I believe this is just the beginning, and I am increasingly confident in our long-term growth prospects” — Rex Geveden, President and CEO · 2026-08-03 — a statement that will be tested at the upcoming Investor Day in September.